NASDAQ · BWV
Healthcare · Biotechnology
$0.18
Down-$0.01 (-6.97%)
Updated Aug 22, 2026, 7:00 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BWV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BWV.
BWV research
Company profile and research snapshot.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 13, 2023 | Maxim Group | Hold | — |
| Apr 26, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 1, 2023 | HC Wainwright & Co. | Buy | — |
| Dec 9, 2022 | HC Wainwright & Co. | Buy | — |
| Dec 8, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 19, 2023
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer, Dr. Neil Campbell.
GlobeNewswire Inc. · Dec 18, 2023
Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer
GlobeNewswire Inc. · Nov 2, 2023
Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team
GlobeNewswire Inc. · Nov 1, 2023
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule").
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BWV.
No results
No recent SID articles mention BWV.
